Imizol Solution, 40ml
Sterile solution for intramuscular or subcutaneous injection.
Composition
1 ml of Imisole contains 120 mg of imidocarb dipropionate
In addition to the active ingredient, it also contains propionic acid (22.34 mg / ml) and water for injection.
Indications
Imisole is used to treat dogs with clinical signs of Babesiosis and / or the presence of Babesia organisms in the blood. Canine babesiosis is a disease caused by tick-borne organisms of the genus Babesia.
Dosage:
Administered intramuscularly or subcutaneously at 6.6 mg / kg (3 mg / lb) body weight. Repeat dose after 2 weeks, for a total of two (2) treatments.
IMIZOL ® Dosing Guideline 6.6 mg / kg body weight
Animal weight | Imisole dose |
10 lbs (4.5 kg) | 0.25 ml |
20 lbs (9.1 kg) | 0.50 ml |
30 lbs (13.6 kg) | 0.75 ml |
40 lbs (18.2 kg) | 1.00 ml |
60 lbs (27.3 kg) | 1.50 ml |
80 lbs (36.4 kg) | 2.00 ml |
100 lbs (45.5 kg) | 2.50 ml |
Caution
Not for human use. Keep out of the reach of children. In case of human exposure, seek immediate medical attention.
It is unacceptable to be administered intravenously. The safety and efficacy of imodocarb has not been determined for puppies or breeding, lactating or pregnant animals. The risk / benefit ratio should be considered before using this drug in dogs with pulmonary, hepatic or renal impairment.
Do not use this product at the same time as exposure to cholinesterase inhibiting drugs, pesticides or chemicals.
ADVERSE REACTIONS
Side effects are often seen as pain during injection and mild [cholinergic signs such as salivation, runny nose or short-term vomiting. Other effects, which are less common, are breathing difficulties, anxiety, diarrhea, and inflammation of the soft spots after the injection last from one to several days. With severe cholinergic symptoms, they can be reversed with atropine sulfate.
Toxicology
IMIZOL solution was administered subcutaneously to four groups of five dogs at a dose of 2.2, 5.5, 7.7, or 9.9 mg / kg. The treatment was repeated after 2 weeks. There were no signs from the use of IMIZOL affecting body temperature, body weight, hematology, most clinical chemical or acute pathologies. With the introduction of the drug at a dose of 9.9 mg / kg, a slight increase in serum alanine aminotransferase (ALT, SGPT) and arginine aminotransferase (AST, AST) was observed, which indicates a slight effect on the liver. Other effects were observed such as pain at the injection site, edema, and vomiting. In two cases, ulcers appeared at the injection site, which were easily cured without complications.
In a 90-day toxicity study, imodocarb was administered orally to three groups of eight dogs at doses of 5, 20, or 80 mg / kg per day. The experiment was carried out to study the toxicity of Imisole to the liver and intestines. These results could be achieved by oral administration of the drug. In pharmacokinetic studies conducted by Abdullah (AS Abdullah et al, Veterinary Research Communications. 1984; (8): 55-59), imodocarb was administered to dogs intravenously at a dose of 4 mg / kg. One of the 13 dogs died. The organs affected by toxicity in this dog were the lungs and kidneys, and some changes were noted in the liver and spleen.
Signs of toxic effects are lethargy, weakness and lack of appetite, possible manifestations of dysfunctions in the side of the gastrointestinal tract, liver, kidneys and lungs.
Pharmacodynamics The
pharmacodynamics of imodocarb have been studied in various forms. Research shows that there is a possibility of adverse reactions that indirectly affect the autonomic nervous system and especially through anticholinesterase mechanisms. Clinical experience in dogs that used the drug at therapeutic doses of less than 10 mg / kg body weight intramuscularly or subcutaneously created a picture of adverse reactions. Such reactions in decreasing order of frequency are salivation, vomiting, and sometimes diarrhea.